Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05347966
Other study ID # CTU: BHSP
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date April 6, 2022
Est. completion date December 2023

Study information

Verified date April 2023
Source Baycrest
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Canadian Therapeutic Platform Trial for Multidomain Interventions to Prevent Dementia (CAN-THUMBS UP, or CTU) is a comprehensive and innovative program aimed to develop, implement and evaluate an interactive and compelling online educational Brain Health Support Program (BHSP) intervention, called Brain Health PRO (BHPro), with potential to positively influence dementia literacy, lifestyle risk factors, and scale-up to reach the broader Canadian public; enroll and retain a community-dwelling Platform Trial Cohort (PTC) of individuals at risk of dementia; and support an open platform trial to test a variety of multidomain interventions that might further benefit individuals at risk of dementia.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 350
Est. completion date December 2023
Est. primary completion date December 2023
Accepts healthy volunteers No
Gender All
Age group 60 Years to 85 Years
Eligibility Inclusion Criteria: 1. Completion and documentation of the electronic Informed Consent Process (from the participant) 2. Sufficient proficiency in English or French to undergo remote clinical and neuropsychological assessment and participate in an online educational program. 3. Technical ability to participate in an online educational program and remote assessments (i.e. computer and internet access; ability to send and receive emails; ability to complete remote assessments) 4. Sufficient vision and hearing to participate in online educational program and to undergo remote clinical and neuropsychological testing 5. Ability to sit comfortably for a period of about 30 minutes 6. Ages 60-85 7. Meets criteria for No Dementia and meet criteria (according to CCNA Criteria, Appendix 1) of one of the following: - Cognitively Unimpaired (CU) - Cognitively Unimpaired plus Subjective Cognitive Impairment (CU + SCI) - Mild Cognitive Impairment (MCI) 8. AND Classified as being at increased risk of dementia based on at least one of the following: - First-degree family history of dementia - Self-Reported or documented current and/or history at midlife (45-60 years) on any of the following lifestyle risk factors: Hypertension (documented Systolic Blood Pressure > 140 mm Hg; OR physician diagnosis of hypertension; OR treatment for hypertension; OR other approaches to treatment (e.g. diet, exercise)) Hypercholesterolemia (documented total cholesterol > 6.5 mmol/L; OR physician diagnosis of hypercholesterolemia; OR treatment for hypercholesterolemia; OR other approaches to treatment (e.g. diet, exercise) Body Mass Index > 30 kg/m2 (derived from NIH Metric BMI Calculator) Physical Inactivity (active is defined as engaging in a minimum of 20- 30 min of physical activity causing sweating and breathlessness, at least 2 times a week) 9. Participant has a family physician or other healthcare provider and agrees to have the provider notified of participation in the study and incidental or other findings that may be clinically significant Exclusion Criteria: 1. Participants who, in the opinion of the investigator, are not able to complete trial procedures remotely or adhere to the schedule of study assessments will be excluded from study participation. 2. Individuals where English or French is not sufficiently proficient for remote clinical assessment, neuropsychological testing and participation in an online educational program. 3. Participants who do not have sufficient vision and hearing for remote clinical assessment, neuropsychological testing participation in an online educational program 4. Individuals who do not have the technical ability to participate in an online educational program. Technical ability is defined as having computer and internet access; ability to send and receive emails; ability to participate in remote assessments 5. Individuals who have a clinical diagnosis of Dementia 6. Clinical Dementia Rating (CDR; telephone/video-conference administration) Score of >1 7. Total Score on the Montreal Cognitive Assessment (MoCA; video-conference administration) <13

Study Design


Intervention

Other:
Brain Health PRO
BHPro is a 45-week, multidomain web-based formal educational program which has been designed to increase dementia literacy, convey best available evidence for lifestyle changes that can mitigate dementia risk, and foster engagement toward one's own brain health.

Locations

Country Name City State
Canada Cape Breton University Cape Breton Nova Scotia
Canada University of New Brunswick Fredericton New Brunswick
Canada Cognitive Clinical Research Group, Parkwood Research Institute London Ontario
Canada Gait and Brain Laboratory, Parkwood Research Institute London Ontario
Canada CRIUGM/ CIUSSS du Centre-Sud-de-l'Île-de-Montréal Montréal Quebec
Canada Baycrest Toronto Ontario
Canada University of British Columbia Vancouver British Columbia

Sponsors (1)

Lead Sponsor Collaborator
Baycrest

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dementia Literacy The primary outcome will be change in dementia literacy following participation in the study, as measured by the Alzheimer's Disease Knowledge Scale. 12 months
Secondary Self-efficacy Change in self-efficacy following participation in the study, as measured by the General Self-Efficacy Scale (GSE). 12 months
Secondary To evaluate usability of BHPro Based on System Usability Scale 12 months
Secondary To evaluate Engagement of BHPro Number of chapters completed on BHPro 12 months
Secondary To evaluate user acceptance of BHPro Based on Technology Acceptance Model Questionnaire 12 months
See also
  Status Clinical Trial Phase
Completed NCT04513106 - Promoting Advance Care Planning for Persons With Early-stage Dementia in the Community: a Feasibility Trial N/A
Recruiting NCT06011681 - The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Active, not recruiting NCT03167840 - Falls Prevention Through Physical And Cognitive Training in Mild Cognitive Impairment N/A
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Not yet recruiting NCT05041790 - A Clinical Trial to Evaluate the Efficacy and Safety of Choline Alfoscerate Compared to Placebo in Patients With Degenerative Mild Cognitive Impairment Phase 4
Recruiting NCT04121156 - High Definition Transcranial Direct Current Stimulation (HD-tDCS) in Patients With Mild Cognitive Impairment N/A
Recruiting NCT03605381 - MORbidity PRevalence Estimate In StrokE
Completed NCT02774083 - Cognitive Training Using Feuerstein Instrumental Enrichment N/A
Completed NCT01315639 - New Biomarker for Alzheimer's Disease Diagnostic N/A
Enrolling by invitation NCT06023446 - Can (Optical Coherence Tomography) Pictures of the Retina Detect Alzheimer's Disease at Its Earliest Stages?
Completed NCT04567745 - Automated Retinal Image Analysis System (EyeQuant) for Computation of Vascular Biomarkers Phase 1
Recruiting NCT05579236 - Cortical Disarray Measurement in Mild Cognitive Impairment and Alzheimer's Disease
Completed NCT03583879 - Using Gait Robotics to Improve Symptoms of Parkinson's Disease N/A
Terminated NCT02503501 - Intranasal Glulisine in Amnestic Mild Cognitive Impairment and Probable Mild Alzheimer's Disease Phase 2
Not yet recruiting NCT03740178 - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005) Phase 1
Active, not recruiting NCT05204940 - Longitudinal Observational Biomarker Study
Recruiting NCT02663531 - Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease N/A
Recruiting NCT06150352 - Sleep Apnea, Neurocognitive Decline and Brain Imaging in Patients With Subjective or Mild Cognitive Impairment
Recruiting NCT03507192 - Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia. N/A